drugset / Trial / NCT00269737

Efficacy of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer

NCT00269737

Phase 3 Completed 7 enrolled Alza Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of continuous use of TTS fentanyl (a transdermal patch delivering the narcotic pain reliever fentanyl) for the treatment of chronic cancer pain.

Timeline

Start
1986-05
Primary completion
Completion
1988-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Fentanyl Other / unclassified 25 ug Other
Subject Fentanyl Other / unclassified 50 ug Other
Subject Fentanyl Other / unclassified 75 ug Other
Subject Fentanyl Other / unclassified 100 ug Other

Indications